Acalabrutinib
- Generic Name
- Acalabrutinib
- Brand Names
- Calquence
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23N7O2
- CAS Number
- 1420477-60-6
- Unique Ingredient Identifier
- I42748ELQW
- Background
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.
...
- Indication
Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. It has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma
- Associated Therapies
- -
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 40
- Registration Number
- NCT02328014
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
- Conditions
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 69
- Registration Number
- NCT02296918
- Locations
- 🇺🇸
Research Site, Columbus, Ohio, United States
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 27
- Registration Number
- NCT02211014
- Locations
- 🇬🇧
Guys and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧United Kingdom, Leicester, United Kingdom
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 113
- Registration Number
- NCT02180711
- Locations
- 🇮🇹
Research Site, Palermo, Italy
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 12
- Registration Number
- NCT02157324
- Locations
- 🇺🇸
Research Site, Fort Worth, Texas, United States
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 21
- Registration Number
- NCT02112526
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 306
- Registration Number
- NCT02029443
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.